So you need a protein - A guide to the production of recombinant proteins by Jayaraj, Ramamoorthi & Smooker, Peter M.
28 The Open Veterinary Science Journal, 2009, 3, 28-34  
 
 1874-3188/09 2009 Bentham Open 
Open Access 
So you Need a Protein - A Guide to the Production of Recombinant Proteins 
Ramamoorthi Jayaraj
1
 and Peter M. Smooker
*,2
 
1
Skin Pathogens Research Laboratory, Menzies School of Health Research, Casuarina, NT, Australia 
2
School of Applied Sciences, RMIT University, Bundoora, Australia 
Abstract: The field of biotechnology owes a great deal to the ability to produce recombinant proteins, which can be made 
in far greater abundance than many native proteins, and are more easily quality controlled. There is a great need for indi-
vidual proteins to be produced for research purposes. This review is aimed at researchers who are not experienced at pro-
tein expression, but find that they have a need to produce a recombinant protein. We detail the major expression systems 
that will be commonly used in the laboratory situation- bacterial, yeast and insect cell culture. The application of each, 
and the relative advantages/disadvantages are discussed. 
INTRODUCTION 
 Recombinant proteins can be used for diagnostic tools, 
vaccines, therapeutic proteins or functional enzymes. Well 
over 150 human and veterinary based biopharmaceuticals 
have received approval and the majority of these approved 
represent recombinant proteins [1] with many being recom-
binant antibodies. While the latter class have limited use in 
the veterinary sector, non-antibody recombinant proteins 
have a large role to play. 
 In the veterinary sector, recombinant protein vaccines are 
being tested extensively and used to control infectious dis-
eases, but are also used to modulate hormones to aid in live-
stock gender selection [2]. “Home-grown” diagnostic kits 
utilising recombinant proteins are often used for research 
purposes to assess immune responses to vaccination or to 
monitor infection. 
 The main driver for the use of recombinant proteins in 
the veterinary sector is the economic loss due to a variety of 
viral, bacterial and parasitological infections of livestock. 
This has been the impetus for research into methods to both 
diagnose and prevent these infections. Veterinary diagnostics 
has traditionally relied on empirical observation of symp-
toms and/or faecal matter, however in order to detect disease 
earlier and therefore at lower pathogen levels more sensitive 
methods are required. The field of diagnosis has been revolu-
tionised by the advent of the Polymerase Chain Reaction 
(PCR), however not all pathogens are amenable to such 
analysis. Sensitive serological methods for detecting immune 
responses induced by pathogens, or the pathogens them-
selves, often require the production of recombinant protein. 
Similarly, much of the research conducted into new veteri-
nary vaccines also involves the production of recombinant 
proteins. Although vaccination has been a major success in 
both the medical and veterinary fields, there are obviously 
numerous infectious diseases that cannot be prevented using  
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traditional attenuated or killed vaccines. Recombinant pro-
teins can play a role in the identification of suitable antigens, 
using a screening methodology, and thus protein expression 
and purification is a key process in the systematic and com-
prehensive analysis of vaccine candidates [3]. Finally, re-
combinant proteins are a preferred source of antigen to use in 
a vaccine, as the quality can be controlled, and the availabil-
ity is usually higher than it is with native protein. 
 A major consideration in the development of recombi-
nant proteins is the choice of expression system, i.e. where is 
the protein to be expressed? The three major main systems 
for the expression of recombinant proteins are Escherichia 
coli, yeast and baculovirus mediated protein expression, al-
though several other systems are available, including other 
bacteria (e.g. Lactococcus lactis), and mammalian cell ex-
pression. Which one is chosen depends primarily on the na-
ture of the heterologous protein to be expressed. In this re-
view, we consider these three most commonly used expres-
sion systems and compare their merits and weaknesses. For 
illustrative purposes we will mainly consider the expression 
of proteases, as these present particular challenges depending 
on the application required. This review is not intended as a 
step-by-step guide to protein production, as these will be 
found with manufacturer’s literature of the system that is 
employed. 
The Methodology 
 The methodology for all expression systems is funda-
mentally similar. The basic requirements are a coding se-
quence for the heterologous protein, a vector (usually a 
plasmid) into which the coding sequence is cloned behind a 
promoter that is active in the chosen host, and a suitable host 
that will then express the heterologous protein. Irrespective 
of the final host (and of course the encoding sequences), the 
cloning of the coding sequence into plasmid and subsequent 
amplification is performed in E. coli. 
 Part of the cloning strategy is that the coding sequence to 
be expressed is cloned in- frame with a second peptide or 
protein, such that the proteins are expressed as a contiguous, 
single unit. These entities are termed affinity tags, which are 
Production of Recombinant Proteins The Open Veterinary Science Journal, 2009, Volume 3    29 
extremely valuable tools for the facilitation of protein purifi-
cation and allow the purification of any tagged recombinant 
protein, irrespective of the intrinsic biochemical properties of 
the protein [4]. These affinity tags will bind to a partner 
ligand, usually immobilised on a resin, such that the protein 
containing the tag is isolated from all other (host) proteins 
that do not bind. A good example is a simple run of six his-
tidine residues, which will co-ordinate divalent cations. Here 
immobilised metal affinity chromatography (IMAC) is used 
to purify a His-tagged protein. There are a variety of differ-
ent tags that are used, from the small His-tag to larger tags 
such as glutathione S- transferase (GST, approx 26 kDa) 
which can have a marked effect on the solubility of the target 
protein [5]. Generally, affinity chromatography will result in 
recombinant protein of acceptable purity. If higher purity is 
required, high performance liquid chromatography (HPLC) 
or size exclusion chromatography (SEC) can be used to im-
prove the purity of the expressed protein [6, 7]. 
 All commonly used expression systems utilise expression 
vectors that encode a tag, such that the coding sequence to be 
expressed is cloned in-frame with the tag. Usually the initia-
tion codon is supplied by the vector sequence, the tag-
encoding sequences follow, and then the sequences encoding 
the heterologous protein are inserted at a cloning site. Often 
there is an encoded protease cleavage site just before the 
cloning site- this allows the removal of the vector-encoded 
sequences (ie: the tag) from the purified protein. Expression 
is driven from a promoter located 5’ to the initiation codon. 
Purification procedures, once a lysate is made from cultured 
cells, are basically the same irrespective of the expression 
system. A schematic representation of the relevant vector 
sequences, and the cloning site for the sequences encoding 
the protein, is shown in Fig. (1). Resultant cleavage of the 
protein to release the N-terminal regions is also shown. 
E. coli Expression Systems 
 The first choice of an expression system for the produc-
tion of recombinant proteins for many investigators is E. coli 
[8]. The E. coli expression system has many advantages 
compared with other expression systems such as easy growth 
conditions, rapid biomass accumulation, and a simple scale-
up process [9]. This prokaryotic organism is often used for 
the industrial production of therapeutic or commercial based 
proteins [9]. It is the system of choice for the expression of 
relatively small, soluble, un-modified proteins, and produces 
over half of the recombinant proteins produced by pharma-
ceutical companies. 
 The scale of expression can vary from several millilitres 
for pilot studies up to thousands of litres in industrial fer-
mentations. Typically, once cloning of insert into expression 
vector has been performed, pilot (small scale purification) is 
used as an screen of expressing clones [3]. Clones expressing 
proteins can be identified by SDS-PAGE and Western blot-
ting with antisera, either directed at the recombinant itself, or 
the tag (typically a monoclonal antibody that recognises the 
His-tag or another tag). An expressing clone is identified and 
used in 50-250 mL culture volumes for further optimisation, 
refinement of expression conditions and optimisation of pu-
rification [8]. 
 In large scale expression, two litres of bacterial culture 
(Luria Bertani broth+ kanamycin + ampicillin) will yield 
approximately 50 to 80 g of wet weight of cells. If the pro-
tein aggregates into inclusion bodies, approximately 100 to 
300 mg of recombinant protein is available (2% to 5% of 
total proteins) [7, 8, 10]. If the protein is soluble (usually 
desirable) yields will be somewhat less. A higher level of 
protein expression can be attained by use of enriched media 
(e.g. terrific broth), which can reduce volumetric require-
ments by increasing cell densities [3, 11]. 
 However, there are limitations to bacterial expression. It 
has been estimated that only 50% of bacterial proteins and 
10% of eukaryotic proteins can be expressed in E. coli in a 
soluble form [12, 13]. This shows that there are many situa-
tions when E. coli may not be the appropriate system. Fur-
thermore, the percentage of expressing soluble proteins de-
creases when the protein molecular weight is above 60 kDa. 
The co-expression of molecular chaperones or heat shock 
proteins with target recombinant proteins can enhance the 
solubility and can help to attain native (i.e. as in the non-
recombinant) conformation [10, 14]. 
 A particular problem in expressing proteins in the E. coli 
cytoplasm is the formation of disulfide bonds, which does 
not occur in the reducing environment of the bacterial cyto-
plasm. This results in the mis-folding of such proteins. This 
can be alleviated by targeting the expressed proteins to the 
periplasm, but often it is more convenient to use a eukaryotic 
host. 
 Another limitation is the inability of E. coli to glycosy-
late proteins. While perhaps not a problem for most veteri-
nary applications, many therapeutic proteins are glycosy-
lated. With the discovery of N-linked glycosylation in some 
bacterial species, much effort is being directed into the crea-
tion of E. coli strains that can add glycans to protein [15]. 
Also, for use such as vaccination or therapeutic protein, the 
bioactivity (if applicable) and the amount of residual LPS 
present in the preparation should be assayed. 
 If a eukaryotic expression system is required, there are 
several alternatives. The simplest is yeast, and the two most 
usually employed are Saccharomyces cerevisiae (Baker’s 
yeast), and the methylotropic yeast Pichia pastoris. 
Yeast Mediated Protein Expression 
 The yeast expression system has been successfully used 
for several decades for the production of heterologous pro-
teins of various origins, either human for therapeutic proteins 
or derived from pathogens for use as vaccines. Yeast are an 
important host used for research purposes to produce pro-
teins that cannot be expressed in an active form in E. coli. In 
a similar way to prokaryote expression in E. coli, yeast has 
advantages such as ease of microbial growth and cultivation 
on inexpensive growth media, while adding the ability to 
perform many post-translational modifications such as O- or 
N- linked glycosylation, phosphorylation, disulphide bridge 
formation, proteolytic processing and folding in a eukaryotic 
system [15-17]. However, there are several complex post-
translational modifications such as prolyl hydroxylation and 
amidation that yeasts cannot perform. 
Saccharomyces cerevisiae 
 Saccharomyces cerevisiae has a long history of use in the 
food and beverage industries, and has been the workhorse for 
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gene expression for several decades. Expression can be 
driven from strong constitutive promoters such as alcohol 
dehydrogenase (ADHI) or enolase (ENO) or from inducible 
promoters (PHO, CUP1, GAL1 and G10). The main advan-
tage of this yeast is to facilitate the direction of foreign pro-
tein into the secretory pathway, by fusion of the mature form 
of the desired recombinant protein to the signal sequence of 
yeast mating factor. Protein folding, formation of disulphide 
bridges and glycosylation occurs during secretion [15, 16]. 
We have used this system extensively for the secretion of 
parasite proteases, as have others [18-22]. 
 One undesirable attribute of S. cerevisiae is the potential 
to hyperglycosylate proteins, which may hinder the antigenic 
properties or function of the protein of interest by masking 
key epitopes or functional sites. In the other direction, the 
hyper-antigenic nature of terminal ?, 1, 3 glycon linkages 
added to expressed proteins makes them unsuitable for 
therapeutic use [16]. For the purposes of generating a protein 
for vaccination purposes, modifications have been made to 
the encoding DNA, such that the amino acids that are the 
target for glycosylation are substituted. For example, we 
have made three codon substitutions in a liver fluke cathep-
sin B clone, substituting Ala for Asn, to remove three poten-
tial N-linked glycosylation sites (recognition sequence N-X-
S/T) from a yeast-expressed protein [20]. However, if the 
natural state of the protein is to be glycosylated, such substi-
tutions may abrogate natural immunogenicity and/or activity. 
 
Fig. (1). Schematic diagram of the construct used to express recombinant protein, and purification of the expressed protein. This 
construct is conceptually similar regardless of the host that it is in, or if it is maintained on a plasmid (E. coli, S. cerevisiae) or integrated into 
the genome (Pichia, Baculovirus). Lines represent non-coding sequences, rectangle are coding sequences. RBS = Ribosome binding site. 
ATG = initiation codon, Tag = (e.g.) sequence encoding 6 x His, GST, etc. Cleavage = sequence encoding recognition sequence for a prote-
ase, Encoded protein= the recombinant protein that is to be expressed, Stop = stop codon. The arrow indicates both the site at which the cod-
ing sequence is inserted in-frame with the preceding sequences (ie: cloning site), and the point at which the protease will cleave the resultant 
recombinant protein. Once the recombinant protein is expressed and purified and proteolytically cleaved, the N- terminal sequences (tag, 
protease recognition sequence) can be removed by affinity chromatography, leaving the desired recombinant as a purified protein. Not drawn 
to scale- usually the coding sequence for the protein will be considerably larger. 
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In these cases, alternative expression systems should be 
sought. 
 Finally, S. cerevisiae generally expresses recombinant 
proteins at a relatively low level. Other species of yeast, of 
which one is detailed below, can lead to significantly higher 
yields. 
Pichia pastoris 
 Pichia pastoris retains all the advantages of expression in 
S. cerevisiae, but yields higher levels of protein [17]. This 
methanotropic yeast can drive expression from the alcohol 
oxidase I (AOX I) promoter, which is one of the strongest 
regulatory promoters known. There is the capacity to fuse 
expression plasmids at specific sites in the P. pastoris ge-
nome, either as single or multiple copy. Furthermore, the 
yeast is easy to grow to very high density in fermenters, en-
suring high levels of recombinant protein production. 
 The AOX I promoter is tightly repressed by glucose and 
induction requires methanol as the carbon source. Although 
this gives maximum induction of recombinant protein ex-
pression, the usage of methanol is considered hazardous (as a 
product of petroleum) which may not be advisable for the 
production of therapeutic proteins [16, 23]. The constitutive 
glyceraldehyde 3 phosphate dehydrogenase (GAP) promoter 
is available to drive expression on glucose and glycerol sub-
strates, and glutathione dependent formaldehyde dehydro-
genase (FLDI) is another promoter that can be induced by 
methylamine (a non-toxic nitrogen source) [24]. 
 Similar to S. cerevisiae, one of the major disadvantages 
of P. pastoris is in the potential for hyperglycosylation. Re-
cent developments have created strains that can partially 
overcome this limitation [25, 26], however an alternative is 
to use insect cells for expression as described below. 
Baculovirus-Mediated Insect Protein Expression 
 The application of insect cells for the production of pro-
teins for commercial use has been expanding [27]. The sys-
tem is based on the ability of recombinant baculovirus to 
infect insect cells, and the foreign protein that is encoded by 
the baculovirus is expressed by the cellular machinery. The 
expression system was first developed for the expression of 
human IFN-? in 1983. Baculovirus- meditated expression 
systems possess a number of advantages: high expression 
levels driven by the strong polyhedrin promoter (see below), 
ability of the insect cells to perform a variety of post-
translational modifications, a high capacity for multiple 
genes or large inserts, and is bio-safe and easy to handle [27, 
28]. Extremely high yields mean that the baculovirus expres-
sion system is an ideal tool for industrial protein production. 
Numerous recombinant proteins produced in insect cells 
have been tested as prophylactic vaccine candidates against 
an array of infectious agents such as HIV, hepatitis C virus, 
enterovirus, severe acute respiratory syndrome corona virus 
(SARS-CoV), dengue virus, rota virus, respiratory syncytial 
virus, human and avian influenza virus and a number of pro-
tozoan parasites. A number of commercially available vac-
cines such as Bajovac CSF E2
Tm 
(Classical swine fever, 
Bayer AG), Ingelvac (porcine circo virus type 2, Boehringer 
Ingelheim) and FluBioK
 Tm 
(HA vaccine, Protein Science 
Corp) are produced in this expression system [11, 28]. 
 The baculovirus genome contains a gene encoding an 
abundant protein, polyhedrin. This protein accumulates in 
infected insect cells (Spodoptera frugiperda Sf9, Trichoplu-
siana and cell lines from Drosophila and Bombyx mori have 
been used) at the end of the infectious cycle, and is then re-
leased into the culture medium. The polyhedrin protein is not 
essential for viral reproduction, and therefore the gene can be 
replaced with a heterologous coding sequence which is then 
expressed at high levels [29]. The system is amenable to 
suspension culture which makes it possible to generate a 
large amount of protein with relatively ease [11]. 
 In order to produce recombinant protein, the heterolo-
gous coding sequence is cloned into a transfer vector which 
targets these sequences to the polyhedrin gene in the viral 
genome. After co-transfection of the transfer vector and viral 
genome into insect cells, the heterologous sequence inserts at 
the appropriate site, behind the late viral strong polyhedrin 
promoter. Compared to bacterial and yeast expression, it is a 
relatively time consuming process to generate clones for 
protein expression and many of the systems commercially 
are designed for more efficient production of recombinant 
viruses, which is a rate-limiting step in using this system. 
 However, one of the major advantages of baculovirus 
expression is that proteins expressed in insect cells are more 
“mammalian-like” than those expressed in bacteria or yeast. 
This is particularly the case where glycosylation is required, 
as the insect cells carry out N-linked glycosylation in a simi-
lar way to mammalian cells, although the attached glycans 
are often not as complex. However, this overcomes the prob-
lem of hyperglycosylation observed in yeast expression sys-
tems. Again, much effort has gone into modifying the bacu-
lovirus expression system to produce glycoproteins with 
mammalian-like glycans attached. 
 If mammalian proteins require post-translational modifi-
cations, and are required with exactly the same properties as 
is expressed in the host, mammalian tissue culture may be 
required. However, as this is extremely unlikely for the ma-
jority of proteins for veterinary application, this will not be 
discussed. 
Choosing a System 
 As indicated earlier, which expression system is used is 
usually dictated by two things: the ultimate use of the prod-
uct, and the nature of the individual protein to be expressed. 
If the protein being expressed requires any form of post-
translational modifications (e.g. disulfide-bond formation, 
attachment of glycans etc) then bacterial expression will 
usually not be optimal, and a eukaryotic system is the best 
choice. Whether this is yeast (S. cerevisiae or P. pastoris), 
baculovirus or even mammalian cell culture depends on the 
modifications required, and how “native” the protein needs 
to be. For efficient secretion of disulfide-bonded proteins, 
yeast is sufficient, while expression in insect cells is superior 
to yeast for glycosylation. 
 As an example, we and others have expressed a variety of 
cathepsin proteases from the liver flukes Fasciola hepatica 
and F. gigantica. These proteases are secreted from the para-
site as pro-enzymes, and contain a number of disulfide 
bonds. For this reason, they are difficult to express in E. coli 
in an active form, as disulfide bonds cannot be formed in the 
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reducing environment of the bacterial cytoplasm (as men-
tioned there are strategies available to enable such expres-
sion by targeting to the periplasm of E. coli). Therefore, ac-
tive proteases have been expressed in either yeast [18-20, 30] 
or in insect cells [21]. As stated, the end-use of the recombi-
nant protein must also be considered. For purposes such as 
determining activity, yeast expression to yield active prote-
ases is used. The advantage of using recombinant proteins 
for this purpose is that it is easy to alter the protein by intro-
ducing a mutation in the coding sequence, and the resulting 
activity change in the protein can be assayed [30]. We have 
also used yeast to generate protein for vaccination [20], al-
though this may not be necessary for some purposes. For 
example, Kesik and colleagues expressed cathepsin protease 
in E. coli, and purified the resultant inclusion bodies which 
were used for vaccination. Although the protein present in 
inclusion bodies will be largely mis-folded, B and T cell 
epitopes will still induce immune responses, which in this 
case were protective. 
 There is also the possibility to purify inclusion body pro-
tein, and refold in vitro to yield active protein. Chow and 
colleagues have devised a set of rules that can be applied to 
many proteins, and this is available as a web server [31]. 
Using a refolding method, we have compared the in vitro 
enzymatic activity of cathepsin L1g expressed in either yeast 
of E. coli. The protease expressed in E. coli was isolated 
from inclusion bodies, and then refolded using step-wise 
urea gradient chromatography, dilution and dialysis. Yeast 
 
Fig. (2). SDS-PAGE analysis of expressed recombinant cathepsin L proteins. (A) E. coli cultures. After induction, 1 mL aliquots of cul-
ture were taken at hourly intervals. Cells were collected by centrifugation, resuspended in phosphate buffer, loading dye added and the sam-
ples electrophoresed. Lane1, marker; lane 2, cell lysate before IPTG induction; lanes 3- 6, lysates from 1 to 4 hrs post-induction. Substantial 
recombinant protein is expressed after induction, indicated by the bold arrow. (B) Purified cathepsin L. Protease was expressed in E. coli, 
purified by His-tag affinity chromatography, and re-folded, or expressed in yeast and purified by affinity chromatography. Lane 1, refolded 
cathepsin L; lane 2, marker; lane 3, yeast-expressed cat L. (C) Western blot analysis using mouse anti-cathepsin L sera. Lanes as for (B). 
Two reactive bands corresponding to pro-protein and mature protein can be observed. (D) SDS-Gelatin PAGE protease activity assay. Lanes 
as for (B). Active protease will digest the gelatine present in the gel, resulting in a cleared region after staining the gel with Coommassie 
blue. Proteolytic activity can be observed in both the E. coli and yeast-expressed samples. Indicative sizes for markers are given in kDa. Pan-
els 1-3 used the same markers. 
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and E. coli derived protease was analysed using Western 
blotting and gelatin-substrate SDS-PAGE, and both were 
shown to exhibit immunoreactivity and proteolytic activity 
(Fig. 2). 
 It is also apparent that not all eukaryotic expression sys-
tems are equal. Cathepsin L was expressed in both yeast and 
insect cells, and then tested for vaccination efficacy in a 
challenge model [21]. Only the baculovirus-mediated protein 
expressed in insect cells was able to induce protection, while 
the yeast expressed protein was ineffective. Part of the rea-
son for this may be that while both systems produced glyco-
sylated protein, the yeast- expressed protein was hyperglyco-
sylated which may mask key epitopes on the surface of the 
protein. As stated above, the ability to make defined muta-
tions in the encoding sequences can alleviate this. We have 
expressed a liver fluke cathepsin B in yeast after eliminating 
each of the three N-linked glycosylation sites present [20]. 
This prevents hyperglycosylation of the protein. 
 The ultimate use of the protein will also determine the 
expression system used. For example, if a protein is being 
used as a diagnostic target for humoral immunity, it may not 
matter if the protein is not in native conformation, as al-
though some conformational epitopes may be lost, there will 
exist linear epitopes that can be recognised. We have previ-
ously expressed a cathepsin L from liver fluke in bacteria, 
and successfully used this (purified from inclusion bodies) in 
an ELISA to measure humoral responses to vaccination and 
infection (Smooker and Spithill, unpublished data). Simi-
larly, producing protein for use in T-cell assays (e.g. ELIS-
POTS) does not necessarily require native protein. 
CONCLUSION 
 The use of recombinant proteins in the veterinary sector 
is likely to increase. For example, as disease monitoring be-
comes a more widespread undertaking, diagnostic kits to 
perform these tasks will be required. Similarly, it is likely 
that many new vaccines will not be based on traditional 
killed or attenuated pathogens, but will be subunit vaccines 
produced as recombinant proteins. 
 Generally speaking, the default system will be bacterial 
expression, as this is the cheapest and easiest to set up. If the 
protein is bacterial, and a soluble protein, it will usually be 
expressed well in such systems, as will a large number of 
soluble eukaryotic proteins. However, some knowledge of 
the structure and ultimate use of your protein product can 
point to the system required, and save time and effort using a 
system not suited to your protein. 
 In deciding on a system to use, questions that can be 
asked include: 
1. Is the protein small, soluble and usually present in the 
cytoplasm? First choice E. coli. 
2. Is the protein normally extracellular, and contains 
disulphide bonds? If yes, consider a eukaryotic sys-
tem (yeast or insect cells). 
3. If (2), does my protein need to be in native conforma-
tion? If no, then E. coli may be sufficient. 
4. Does my protein require glycosylation? If yes, use 
yeast or insect cells. 
5. Is the protein prone to hyperglycosylation? If yes, use 
Pichia or insect cells in preference to S. cerevisiae. 
6. Is my protein usually glycosylated, but this is not re-
quired for the application? If yes, express in E. coli if 
possible, or mutagenise amino acids in the glycosyla-
tion recognition sequence and express in eukaryotic 
systems. 
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